More articles from Supplement

Pathogenic mechanisms in giant cell arteritis
Cornelia M. Weyand, MD and Jörg J. Goronzy, MD
Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 2) SII-28-SII-32;
Classification of anti–endothelial cell antibodies into antibodies against microvascular and macrovascular endothelial cells: the pathogenic and diagnostic implications
Yehuda Shoenfeld, MD
Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 2) SII-65-SII-66;
Diffuse Endothelial Dysfunction is a Common Feature of SNV
PA Bacon, RJ Stevens, DM Carruthers, AD Diler, K Raza and J Townend
Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 2) SII-109;
Diagnostic Modalities, Surrogate Markers of Disease Activity, and Tools for Outcome Measurements
Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 2) SII-171-SII-179;
Cyclooxygenase-2–selective inhibitors in the management of acute and perioperative pain
Warren A. Katz, MD
Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 1) SI-65-SI-75;
Implications for pathogenesis of patterns of injury in small- and medium-sized-vessel vasculitis
J. Charles Jennette, MD
Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 2) SII-33-SII-38;
HMG-CoA Reductase Inhibitors Decrease Anca-Mediated Activation Of Human Neutrophils
M Choi, S Rolle, M Rane, H Haller, FC Luft and R Kettritz
Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 2) SII-68;
Conventional treatment and outcome of Wegener’s granulomatosis and microscopic polyangiitis
David R.W. Jayne, MD
Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 2) SII-110-SII-115;
Treatment and Outcomes
Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 2) SII-179-SII-191;
Emerging options with coxib therapy
Mark J. Lema, MD, PhD
Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 1) SI-76-SI-84;

Pages